BRPI0407832A - inibidor de pten ou abridor dos canais maxi-k - Google Patents

inibidor de pten ou abridor dos canais maxi-k

Info

Publication number
BRPI0407832A
BRPI0407832A BRPI0407832-2A BRPI0407832A BRPI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A
Authority
BR
Brazil
Prior art keywords
maxi
medicine
pten
opener
channel opener
Prior art date
Application number
BRPI0407832-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Ki Whan Hong
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0407832A publication Critical patent/BRPI0407832A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0407832-2A 2003-02-25 2004-02-24 inibidor de pten ou abridor dos canais maxi-k BRPI0407832A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US44958903P 2003-02-26 2003-02-26
PCT/JP2004/002146 WO2004075897A1 (en) 2003-02-25 2004-02-24 Pten inhibitor or maxi-k channels opener

Publications (1)

Publication Number Publication Date
BRPI0407832A true BRPI0407832A (pt) 2006-02-14

Family

ID=32930512

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407832-2A BRPI0407832A (pt) 2003-02-25 2004-02-24 inibidor de pten ou abridor dos canais maxi-k

Country Status (19)

Country Link
US (3) US7825130B2 (https=)
EP (1) EP1599205B1 (https=)
JP (3) JP4590397B2 (https=)
KR (1) KR101031163B1 (https=)
CN (2) CN101829116B (https=)
AR (1) AR043379A1 (https=)
AT (1) ATE345800T1 (https=)
AU (1) AU2004216340B9 (https=)
BR (1) BRPI0407832A (https=)
CA (1) CA2515590C (https=)
CY (1) CY1106294T1 (https=)
DE (1) DE602004003348T2 (https=)
DK (1) DK1599205T3 (https=)
ES (1) ES2276282T3 (https=)
MX (1) MXPA05008996A (https=)
MY (1) MY136863A (https=)
PT (1) PT1599205E (https=)
TW (1) TWI323660B (https=)
WO (1) WO2004075897A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
RU2469723C2 (ru) * 2007-05-22 2012-12-20 Оцука Фармасьютикал Ко., Лтд. Лекарственное средство, содержащее производное карбостирила и донепезил, для лечения болезни альцгеймера
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
AU2009205771B2 (en) 2008-01-17 2014-12-11 Kui Liu Methods for in vitro maturation of ovarian follicles
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
US20110189308A1 (en) * 2008-03-17 2011-08-04 Asa Abeliovich Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
EP2502623B1 (en) * 2008-06-06 2016-04-06 Children's Medical Center Corporation Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation
CA2777628C (en) 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
KR20150027800A (ko) 2012-06-15 2015-03-12 고에키 자이단 호징 센탄 이료 신코 자이단 경도 인지 장해의 예방 및/또는 치료제
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
WO2017199755A1 (ja) * 2016-05-19 2017-11-23 国立研究開発法人国立循環器病研究センター 認知症の予防及び／又は治療のための薬剤
EP4151213A4 (en) * 2020-05-11 2024-05-29 Shimadzu Corporation THERAPEUTIC FOR MILD COGNITIVE IMPAIRMENT

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
AU5715994A (en) * 1992-12-24 1994-07-19 Otsuka Pharmaceutical Co., Ltd. Psoriasis remedy
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
MXPA00010254A (es) * 1998-05-01 2002-08-06 R Cutler Neal Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
DE602004003348T2 (de) 2007-05-31
EP1599205A1 (en) 2005-11-30
AU2004216340A1 (en) 2004-09-10
US8653104B2 (en) 2014-02-18
JP5566482B2 (ja) 2014-08-06
US7825130B2 (en) 2010-11-02
EP1599205B1 (en) 2006-11-22
WO2004075897A1 (en) 2004-09-10
CA2515590A1 (en) 2004-09-10
ES2276282T3 (es) 2007-06-16
JP2006518732A (ja) 2006-08-17
JP2013082735A (ja) 2013-05-09
TW200501954A (en) 2005-01-16
AU2004216340B2 (en) 2008-07-31
MY136863A (en) 2008-11-28
PT1599205E (pt) 2007-01-31
JP5208172B2 (ja) 2013-06-12
CN101829116A (zh) 2010-09-15
ATE345800T1 (de) 2006-12-15
DK1599205T3 (da) 2007-03-26
US20130065921A1 (en) 2013-03-14
US20100113515A1 (en) 2010-05-06
KR20050098960A (ko) 2005-10-12
US8329731B2 (en) 2012-12-11
HK1148225A1 (zh) 2011-09-02
DE602004003348D1 (de) 2007-01-04
JP2010285456A (ja) 2010-12-24
MXPA05008996A (es) 2005-10-18
TWI323660B (en) 2010-04-21
CA2515590C (en) 2011-09-13
US20060154963A1 (en) 2006-07-13
HK1091409A1 (en) 2007-01-19
KR101031163B1 (ko) 2011-04-27
AR043379A1 (es) 2005-07-27
CN101829116B (zh) 2015-11-25
AU2004216340B9 (en) 2008-09-18
CY1106294T1 (el) 2011-10-12
JP4590397B2 (ja) 2010-12-01
CN1780623B (zh) 2011-09-14
CN1780623A (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
BRPI0407832A (pt) inibidor de pten ou abridor dos canais maxi-k
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
BRPI0520588A2 (pt) composições farmacêuticas para o tratamento de distúrbios do ouvido interno
JP2005527512A5 (https=)
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2547445A1 (en) Systems and methods for altering vestibular biology
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
BRPI0418195A (pt) aplicação de rotigotina para o tratamento ou a prevenção da perda de neurÈnios dopaminérgicos
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
WO2003032921A3 (en) Treatment of neurodegenerative diseases and cancer of the brain
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
BR0207272A (pt) Método de tratamento de doenças ou condições de desmielinação
WO2002062327A3 (en) Method of treating neurological disorders using acetone derivatives
WO2005016272A3 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
US5952388A (en) Use of selegiline for the treatment of epileptic disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.